Vivek Subbiah, MD Department of Investigational Cancer Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center

Retevmo® (selpercatinib) Demonstrates Activity Against Advanced RET Fusion Positive Advanced Solid Tumors

MedicalResearch.com Interview with:

Vivek Subbiah, MD Department of Investigational Cancer Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center

Dr. Subbiah

Vivek Subbiah, MD
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center

MedicalResearch.com: What is the background for this study?

Response: RET fusions occur predominantly in 2% of lung cancers and 10-20% of thyroid cancers, and in low frequency in an increasing number of diverse cancers, including pancreatic cancer, salivary gland cancer, and colorectal cancer. The therapeutic relevance of RET fusions occurring outside of lung and thyroid cancers has not been well established..

MedicalResearch.com: What are the main findings?

Response: Selpercatinib is a first-in-class highly selective and potent CNS-active RET kinase inhibitor and has received approval in multiple countries including the United States and Europe for the treatment of RET fusion-positive lung as well as RET-driven thyroid cancers. Selpercatinib demonstrates promising activity across a variety of non-lung and non-thyroid RET fusion positive advanced solid tumors, including treatment-refractory GI malignancies

MedicalResearch.com: What should readers take away from your report?

Response: RET fusions in tumors other than non-small cell lung cancer and thyroid cancer are uncommon but potentially actionable. The objective response rate by investigator’s assessment in this heavily pretreated patient population was 47% and included complete responses, and the efficacy was observed across cancer types and a spectrum of fusion partners.

MedicalResearch.com: What recommendations do you have for future research as a result of this work? 

Response: These analyses reiterate the importance of broad-based genomic profiling to identify actionable oncogenic drivers, including RET fusions.

Citation: AACR 2021 Abstract

CT011 – Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers

Vivek SubbiahBhavana KondaTodd BauerCaroline McCoachGerald FalchookMasayuki TakedaJyoti PatelJared WeissNir PeledLyudmila BazhenovaVictoria SoldatenkovaPearl FrenchNora DroveOliver GautschiAlexander Drilon. MD Anderson Cancer Center, Houston, TX, The Ohio State University Comprehensive Cancer Center, Columbus, OH, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, Sarah Cannon Research Institute at HealthONE, Denver, CO, Kindai University Hospital Faculty of Medicine, Osaka, Japan, Northwestern University Feinberg School of Medicine, Chicago, IL, University of North Carolina Chapel Hill, Chapel Hill, NC, Shaare Zedek Medical Center, Jerusalem, Israel, University of California San Diego, San Diego, CA, Eli Lilly and Company, Indianapolis, IN, University of Berne and Cantonal Hospital of Luzerne, Luzerne, Switzerland, Memorial Sloan Kettering Cancer Center, New York, NY

JOIN OUR EMAIL LIST

We respect your privacy and will never share your details.

Apr 12, 2021 @ 11:39 pm 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.